Claremont, CA (PRWEB) April 29, 2013
Disease causing bacteria shield themselves in wounds from antibiotics by creating protective environments called biofilms. Wound infections that are contaminated with bacterial biofilms lead to delayed healing and increased inflammation. Because of the inability of antibiotics to effectively kill all of the bacteria in the biofilm, these biofilms also help the bacteria to develop multi-drug resistance.
Acinetobacter baumannii, a bacterium that is naturally resistant to most antibiotics, is a particular concern in healthcare settings. Acinetobacter rapidly forms biofilms that are very difficult to treat and are prevalent in hospitals and among soldiers injured in Iraq. More than 3,300 U.S. injured troops have developed Acinetobacter infections in military hospitals. Acinetobacter is also a well-documented civilian hospital pathogen, particularly in ICU and trauma patients. It can live on dry environmental surfaces in an ICU for up to 13 days, and has been recovered from various sites in the patients’ environment, including bed curtains, bed rails, furniture, and hospital equipment.
Synedgen has developed a new approach to topical treatment of bacterial infections that does not rely on traditional antibiotics or their mechanisms of action. Synedgen’s novel, non-toxic biopolymer, SY203, clumps bacteria and disrupts adhesion of biofilms to facilitate safe and effective removal from the wound. In animal and in vitro studies, SY203 has been shown to have residual activity to prevent adhesion of bacteria to wound tissue, providing a protective, long-term barrier to colonization. Using this novel treatment, it is not necessary to try to kill all of the bacteria in order to treat the infection. The use of antibiotics with sub-therapeutic killing is the major source of generation of antibiotic resistance.
Topical antiseptics, such as hydrogen peroxide, Sulfamylon® and silver sulfadiazine (SSD) can kill bacteria, but they are also damaging to the underlying tissue and slow down wound healing.
With funding from the Defense Advanced Research Projects Agency (DARPA), Stephen C. Davis, Director of the Pre-Clinical Wound Healing & Infection Research at the University of Miami Health System, led an independent study assessing Synedgen’s active ingredient against high dose, standard of care wound treatment SSD to reduce Acinetobacter biofilm formation. Synedgen’s biopolymer prevailed over all treatments, reducing bioburden by 99.98% after 3 days of treatment. SY203 continued to successfully eliminate more bacteria from day 3 to 4 than did SSD (84% more vs. 56%).
Dr. Davis will present these results at a poster presentation entitled The Use of a Novel Non-toxic Biopolymer to Treat Acinetobacter Baumannii Wound Biofilms at the Symposium on Advanced Wound Care and Wound Healing Society (SAWC/WHS) at the Colorado Convention Center in Denver May 1-5, 2013. SAWC/WHS is the premier interdisciplinary wound care program and is the largest annual gathering of wound care clinicians in the United States.
"These studies in a highly regarded porcine model have demonstrated the effectiveness of SY203 to remove Acinetobacter from biofilms in wounds, a treatment that is not only more effective than SSD (p<.005), but that is also less toxic to the damaged tissue and more conducive to wound healing. These results confirm our observations on healing and infection control in previous animal and in vitro studies,” stated Synedgen president Shenda Baker. “Synedgen is eager to translate these findings into human clinical trials and provide alternatives to traditional wound treatments in both acute and chronic clinical settings.”